<DOC>
	<DOCNO>NCT02087644</DOCNO>
	<brief_summary>A phase IIb study patient evaluate CYT003- QbG10 versus placebo , patient mild moderate allergic asthma sufficiently control inhaled steroid . Altogether 170 patient , randomize two treatment group include . Key outcome measure patient report parameter asthma</brief_summary>
	<brief_title>CYT003 Patients With Mild Moderate Allergic Asthma Not Sufficiently Controlled Inhaled Glucocorticosteroids</brief_title>
	<detailed_description>A phase IIb study patient evaluate CYT003- QbG10 versus placebo , patient mild moderate allergic asthma sufficiently control inhaled steroid . Altogether 170 patient , randomize two treatment group include . Key outcome measure patient report parameter asthma time primary endpoint throughout study .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Provide write informed consent . 2 . Complete protocol requirement . 3 . Between 18 65 year age . 4 . Persistent allergic asthma patient 5 . Forced expiratory volume one second ( FEV1 ) ≥60 % ≤ 90 % predict value 6 . Reversibility airway obstruction 7 . Patients meet contraception requirement 8 . At baseline : Patients treat ICS insufficiently control 9 . Blood eosinophil count certain level 1 . Failure meet least 80 % compliance use patient ediary/ peak expiratory flow ( PEF ) meter ( AM3 device ) baseline visit 2 . Treatment hospitalization asthma exacerbation within past 2 month 3 . Current use use systemic corticosteroid within past 2 month 4 . Current smoker . 5 . Exsmokers less 1 year , tobacco smoke history &gt; 10 pack year 6 . Major surgery within 3 month prior sign ICF anticipate study 7 . Presence history clinically relevant cardiovascular , renal , pulmonary ( e.g . COPD ) , endocrine , autoimmune , dermatological , neurological , psychiatric , ocular disease judge investigator . 8 . Any malignancy within previous 5 year 9 . Presence suspicious lymphadenopathy splenomegaly physical examination . 10 . Confirmed suspected current infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) . 11 . Presence active infectious disease judge investigator 12 . Active autoimmune disease prior diagnosis autoimmune disease include limited rheumatoid arthritis , lupus ulcerative colitis . 13 . Pregnancy ( base positive urine test screen visit ) lactation . 14 . Female plan become pregnant study period . 15 . Patients history abuse alcohol recreational drug . 16 . Ongoing plan specific immunotherapy ( SIT ) whole study period SIT complete within last 3 year . 17 . BMI &gt; 40 18 . Use investigational approve biologics/immunemodulators within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>